Horn Jeffrey D
Vision For Life, Nashville, Tennessee 37203, USA.
Curr Opin Ophthalmol. 2007 Feb;18(1):58-61. doi: 10.1097/ICU.0b013e328011f9bf.
To provide an update on the status of toric intraocular lenses. These lenses can be used as an alternative or adjunct to corneal astigmatic incisions for correcting preexisting astigmatism in patients with cataracts. They are a particularly attractive option in those cases where limbal-relaxing incisions are not powerful or predictable enough. Other toric lenses may correct astigmatism in addition to spherical refractive errors in phakic patients.
Toric lenses have continued to gain popularity with the US Food and Drugs Administration (FDA) approval of the Acrysof Toric intraocular lenses. This lens is designed to be implanted in patients undergoing cataract removal and who have significant preexisting corneal astigmatism. In the FDA clinical trial, study patients received one of the three cylindrical powers, and control patients received a standard monofocal intraocular lenses. The study found that the Acrysof Toric intraocular lenses provided excellent visual outcomes and exhibited excellent rotational stability. With the Acrysof Toric intraocular lenses, the average lens rotation was less than 4 degrees from the lens' initial placement at 6 months after surgery.
Toric intraocular lenses provide excellent vision for astigmatic cataract patients, and new designs are significantly improving visual acuity by minimizing the risk of rotation.
提供关于散光型人工晶状体现状的最新信息。这些晶状体可作为角膜散光切口的替代方法或辅助手段，用于矫正白内障患者术前存在的散光。在角膜缘松解切口不够有效或可预测性不足的情况下，它们是特别有吸引力的选择。其他散光型晶状体还可矫正有晶状体眼患者的球面屈光不正及散光。
随着美国食品药品监督管理局（FDA）批准爱尔康散光型人工晶状体，散光型晶状体越来越受欢迎。该晶状体设计用于接受白内障摘除且术前存在明显角膜散光的患者。在FDA临床试验中，研究患者接受三种柱镜度数之一，对照患者接受标准单焦点人工晶状体。研究发现，爱尔康散光型人工晶状体提供了出色的视觉效果，且表现出出色的旋转稳定性。使用爱尔康散光型人工晶状体时，术后6个月晶状体平均旋转角度距初始位置小于4度。
散光型人工晶状体为散光性白内障患者提供了出色的视力，新设计通过将旋转风险降至最低显著提高了视力。
